I promise, no mention of the fiscal cliff today! Cross my heart and hope to go into a tryptophan-induced coma!

With Thanksgiving feasts soon being prepared in countless kitchens across America, and trading volume extremely light, all attention was turned to the temporary cease-fire announced between Israel and Hamas in the Gaza Strip. Hope, even in the slightest, that this peace will be lasting sent the broad-based S&P 500 (SNPINDEX:^GSPC) higher by 3.22 points (0.23%) to 1,391.03.

Medical-device companies are making waves in the S&P 500 with St. Jude Medical (NYSE:STJ) leading the charge lower by 12%, and its peer Boston Scientific (NYSE:BSX) heading higher by 5%. Earlier today, the Food and Drug Administration released a report that claims St. Jude's lead that connects a defibrillator to the heart, known as Durata, was inadequately verified through testing. Having suffered through a recall on a previous version of this lead, known as Riata, St. Jude shareholders are experiencing a case of deja vu. Boston Scientific, on the other hand, is enjoying every minute, as it could give the lead manufacturer a chance to recapture market share.

Cloud-based software provider salesforce.com (NYSE:CRM) was the index's biggest winner, rising nearly 9%, after squeaking past Wall Street's third-quarter earnings projections. For the quarter, Salesforce earned an adjusted $0.33, $0.01 higher than the consensus estimate, as revenue rose 35% to $788.4 million. Keep in mind, though, that expenses are beginning to rise just as rapidly as, if not faster than, revenue growth. Valued at a frothy 80 times forward earnings and with its growth rate likely to slow, I see no reason investors should be paying such a premium for this cloud-based software company.

On the downside, Best Buy (NYSE:BBY) shares continued their slide, down another 3%, just a day after reporting an adjusted profit that widely missed analysts' expectations as same-store sales declined 4.3%. To make matters worse, ratings agency Fitch downgraded Best Buy's debt rating to BB- from BB+ and placed an outlook of "negative" on the big-box retailer as it sees the company's attempt to retain its current market share as utopian at best. CEO Hubert Joly has the next three months to prove shareholders wrong -- otherwise, it could be lights out for another big box retailer.

Step out of the box
Best Buy may not have the formula for ruling the retail landscape, but three companies recently highlighted by our analysts at Stock Advisor do have all of the tools needed to rule retail. Click here to get your copy of this latest special report, for free, and find out which three companies have the tools necessary to succeed in a rapidly shifting retail environment.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.